Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16040722rdf:typepubmed:Citationlld:pubmed
pubmed-article:16040722lifeskim:mentionsumls-concept:C0034785lld:lifeskim
pubmed-article:16040722lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16040722lifeskim:mentionsumls-concept:C0443199lld:lifeskim
pubmed-article:16040722lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:16040722lifeskim:mentionsumls-concept:C0127400lld:lifeskim
pubmed-article:16040722pubmed:issue6lld:pubmed
pubmed-article:16040722pubmed:dateCreated2005-11-14lld:pubmed
pubmed-article:16040722pubmed:abstractTextRecent data suggest that beta-adrenergic receptor subtypes couple differentially to signaling pathways regulating cardiac function vs. cardiac remodeling. To dissect the roles of beta1- vs. beta2-receptors in the pathogenesis of cardiomyopathy, doxorubicin was administered to beta1, beta2, and beta1/beta2 knockout (-/-) and wild-type mice. Expression and activation of MAPKs were measured. Wild-type and beta1-/- mice showed no acute cardiovascular effects, whereas beta2-/- mice all died within 30 min. The additional deletion of the beta1-receptor (beta1/beta2-/-) totally rescued this toxicity. beta2-/- mice developed decreased contractile function, hypotension, QTc prolongation, and ST segment changes and a 20-fold increase in p38 MAPK activity not seen in the other genotypes. The MAPK inhibitor SB-203580 rescued beta2-/- mice from this acute toxicity. The enhanced toxicity in beta2-/- mice was also recapitulated in wild-type mice with the beta2-selective antagonist ICI-118,551, although the rescue effect of the beta1-deletion was not recapitulated using the beta1-selective antagonist metoprolol or the nonselective beta-antagonist propranolol. These data suggest that beta2-adrenergic receptors play a cardioprotective role in the pathogenesis of cardiomyopathy, whereas beta1-adrenergic receptors mediate at least some of the acute cardiotoxicity of anthracyclines. Differential activation of MAPK isoforms, previously shown in vitro to regulate beta-agonist as well as doxorubicin cardiotoxicity, appears to play a role in mediating the differential effects of these beta-adrenergic receptor subtypes in vivo.lld:pubmed
pubmed-article:16040722pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16040722pubmed:languageenglld:pubmed
pubmed-article:16040722pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16040722pubmed:citationSubsetIMlld:pubmed
pubmed-article:16040722pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16040722pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16040722pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16040722pubmed:statusMEDLINElld:pubmed
pubmed-article:16040722pubmed:monthDeclld:pubmed
pubmed-article:16040722pubmed:issn0363-6135lld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:KobilkaBrian...lld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:ZhaoMingmingMlld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:BernsteinDani...lld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:UrashimaTakas...lld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:BerryGeraldGlld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:PowersJennife...lld:pubmed
pubmed-article:16040722pubmed:authorpubmed-author:FajardoGiovan...lld:pubmed
pubmed-article:16040722pubmed:issnTypePrintlld:pubmed
pubmed-article:16040722pubmed:volume289lld:pubmed
pubmed-article:16040722pubmed:ownerNLMlld:pubmed
pubmed-article:16040722pubmed:authorsCompleteYlld:pubmed
pubmed-article:16040722pubmed:paginationH2441-9lld:pubmed
pubmed-article:16040722pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:meshHeadingpubmed-meshheading:16040722...lld:pubmed
pubmed-article:16040722pubmed:year2005lld:pubmed
pubmed-article:16040722pubmed:articleTitleDifferential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes.lld:pubmed
pubmed-article:16040722pubmed:affiliationDept. of Pediatrics, 750 Welch Rd., Suite 305, Palo Alto, CA 94304, USA. danb@stanford.edulld:pubmed
pubmed-article:16040722pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16040722pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16040722pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:11554entrezgene:pubmedpubmed-article:16040722lld:entrezgene
entrez-gene:11555entrezgene:pubmedpubmed-article:16040722lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16040722lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16040722lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16040722lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16040722lld:pubmed